Approval marks first new class of treatment in decades and the first muscarinic agonist
The centrally acting alpha2-adrenergic agonist is approved for patients ≥6 years
Authors urge greater transparency of study results for drugs approved by the FDA
Zurzuvae works faster than conventional antidepressants and is easier to take than another postpartum depression drug that is delivered intravenously
For first three approved indications, second and third indication approvals less likely to have high value rating
While Leqembi did help reduce mental decline compared with placebo, the drug has been linked to two deaths from brain bleeds
Patients who received 2 or 3 mg of Rexulti had significant improvements in agitation scores compared with patients taking a placebo
Approval is for treatment of excessive daytime sleepiness with once-at-bedtime dosing
The spray can already be obtained without a prescription, but currently buyers must get it from a pharmacist
Findings seen for 21 drug approvals between 2018 and 2021, with only one-third needing postmarketing studies